Liraglutide Attenuates Myocardial Fibrosis via Inhibition of AT1R-Mediated ROS Production in Hypertensive Mice
The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Abstract
Background/Aims: Glucagon-like peptide-1 receptor agonist liraglutide has been reported to exert cardioprotective effects, but its effect on cardiac fibrosis remains controversial. The aim of this study was to investigate the effects of liraglutide on cardiac fibrosis and potential mechanisms. Methods: C57BL/6 mice (3-month old) were randomly divided into control, hypertension, and hypertension + liraglutide groups. The hypertensive state was created by infusion of Ang II (100 ng/kg·min) for 4 weeks through subcutaneously implanted osmotic pumps. The control mice were infused with saline. Mice were also given vehicle or liraglutide (400 μg/kg·day). Blood pressure (BP), blood sugar, myocardial fibrosis, AT1R expression, and reactive oxygen species (ROS) levels were measured. To further elucidate the mechanisms of fibrosis, mouse cardiac fibroblasts were isolated and treated with liraglutide (300 nM/L) or losartan (10 μM) for 3 hours, followed by Ang II (10 −7 M) for additional 12 hours. Reactive oxygen species production and expressions of collagen-1 and -3 were measured. Results: Liraglutide reduced BP and blood sugar but did not affect the body weight of the hypertensive mice. Liraglutide also inhibited collagen accumulation, AT1R expression, and ROS generation in the hearts of the hypertensive mice. In in vitro studies, pretreatment with liraglutide and losartan (as control) markedly inhibited Ang II-induced ROS production and collagen expression in the cultured cardiac fibroblasts. Conclusion: Liraglutide reduces myocardial fibrosis in the hypertensive mice, which appears to be dependent on at least in part inhibition of ROS production.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“For instance, they may mitigate cardiac fibroblast development and myocardial fibrosis by modulating the CD36-JNK-AP1 pathway, which reduces P4HA1 levels, blocking ROS production mediated by the Ang II type I receptor.”
From Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications (2024) · cites this paper as [49]
Citations
Cites
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629 · cited 1×
“More importantly, clinical trials also indicated that liraglutide did not reduce the rates of nonfatal myocardial infarction and hospitalizations for heart failure.(17) It is possible that the species specificity may be one of the main factors behind the controversy.”
BackgroundGlobal Public Health Burden of Heart Failure
Savarese, G., Lund, L. H., Division of Cardiology, D. O. M., Department of Cardiology, K. U. H., Division of Cardiology, D. O. M., & Department of Cardiology, K. U. H. (2017) · Cardiac Failure Review · doi:10.15420/cfr.2016:25:2 · Cited by 2,641 · cited 1×
“Heart failure is a major health problem affecting 20 to 30 million people around the world.(1) Myocardial fibrosis, the excess deposition of extracellular matrix in the ventricular wall, is a hallmark of mid- to late-stage heart failure, which occurs in long-standing hypertension.”
BackgroundCardiac fibrosis in myocardial infarction—from repair and remodeling to regeneration
Talman, V., & Ruskoaho, H. (2016) · Cell and Tissue Research · doi:10.1007/s00441-016-2431-9 · Cited by 905
Myocardial Interstitial Fibrosis in Heart Failure
González, A., Schelbert, E. B., Díez, J., & Butler, J. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.02.021 · Cited by 660 · cited 2×
“Myocardial fibrosis, the excess deposition of extracellular matrix in the ventricular wall, is a hallmark of mid- to late-stage heart failure, which occurs in long-standing hypertension.(2) The persistent pressure overload causes excessive accumulation of collagens, mainly collagen type I and type III fibers, in the i…”
BackgroundThe origin of fibroblasts and mechanism of cardiac fibrosis
Krenning, G., Zeisberg, E. M., & Kalluri, R. (2010) · Journal of Cellular Physiology · doi:10.1002/jcp.22322 · Cited by 601 · cited 1×
“The abnormal secretion of collagen from cardiac fibroblasts is thought to be the basis of cardiac fibrosis.(29) It is known that both hypertension and diabetes are independent risk factors for Figure 6.”
BackgroundNoyan-Ashraf, M. H., Momen, M. A., Ban, K., Sadi, A.-M., Zhou, Y.-Q., Riazi, A. M., Baggio, L. L., Henkelman, R. M., Husain, M., & Drucker, D. J. (2009) · Diabetes · doi:10.2337/db08-1193 · Cited by 575 · cited 2×
“Some studies showed that liraglutide exerts cardioprotective effects in animal and clinical studies.(15,16) Bizino et al reported that liraglutide could reduce the infarct volume and slow the progression of diabetic cardiomyopathy in patients with type 2 diabetes.”
BackgroundRusso, I., & Frangogiannis, N. G. (2016) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2015.12.011 · Cited by 474
The Cardiac Renin-Angiotensin System: Conceptual, or a Regulator of Cardiac Function?
Dostal, D. E., & Baker, K. M. (1999) · Circulation Research · doi:10.1161/01.res.85.7.643 · Cited by 398 · cited 2×
“The activation of renin-angiotensin system (RAS) and subsequent release of Ang II is thought to play a role in the development of hypertension and myocardial fibrosis via stimulation of AT1R.(4,5) Development of fibrosis, which leads to a progressive increase of ventricular stiffness and impaired diastolic function, i…”
BackgroundLim, D.-S., Lutucuta, S., Bachireddy, P., Youker, K., Evans, A., Entman, M., Roberts, R., & Marian, A. J. (2001) · Circulation · doi:10.1161/01.cir.103.6.789 · Cited by 386 · cited 1×
“Losartan effectively reverses myocardial fibrosis in the murine hypertensive models.(37,38) Based on the similarity of actions of losartan and liraglutide, it may be concluded that liraglutide acts as an anti-fibrosis drug works in part by inhibiting AT1R-ROS axis.”
BackgroundCardiac fibrosis: new insights into the pathogenesis
Ma, Z.-G., Yuan, Y.-P., Wu, H.-M., Zhang, X., & Tang, Q.-Z. (2018) · International Journal of Biological Sciences · doi:10.7150/ijbs.28103 · Cited by 331 · cited 1×
“Despite the high prevalence of diastolic heart failure, there are currently no effective remedies to control or inhibit cardiac fibrosis and improve the clinical state.(9) Glucagon-like peptide 1 (GLP-1) is an incretin hormone that enhances insulin secretion through adenylyl cyclase, inhibits glucagon secretion, delay…”
Background
Research works printed but not linked: 2
- Huang DD, 2018, Eur Rev Med Pharmacol Sci, 22, 4648
- Li R, 2019, Front Pharmacol, 10, 10537
Cited by
Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications
Alharbi, S. H. (2024) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/20420188231222367 · Cited by 358
GLP-1 receptor agonists (GLP-1RAs): cardiovascular actions and therapeutic potential
Ma, X., Liu, Z., Ilyas, I., Little, P. J., Kamato, D., Sahebka, A., Chen, Z., Luo, S., Zheng, X., Weng, J., et al. (2021) · International Journal of Biological Sciences · doi:10.7150/ijbs.59965 · Cited by 299
“For example, GLP-1RAs may modulate the CD36-JNK-AP1 pathway by partially down-regulating prolyl 4-hydroxylase subunit alpha-1 (P4HA1), and then inhibit ROS production mediated by Ang II type I receptor, thereby ameliorating cardiac fibroblast proliferation and myocardial fibrosis [167, 168].”
BackgroundKhavinson, V., Linkova, N., Dyatlova, A., Kantemirova, R., & Kozlov, K. (2022) · Cells · doi:10.3390/cells12010106 · Cited by 62
Diabetes and Myocardial Fibrosis
Salvador, D., Gamba, M., González-Jaramillo, N., González-Jaramillo, V., Raguindin, P. F., Minder, B., Gräni, C., Wilhelm, M., Stettler, C., Doria, A., et al. (2022) · JACC. Cardiovascular imaging · doi:10.1016/j.jcmg.2021.12.008 · Cited by 72
Targeting redox imbalance in neurodegeneration: characterizing the role of GLP-1 receptor agonists
Ghosh, P., Fontanella, R. A., Scisciola, L., Pesapane, A., Taktaz, F., Franzese, M., Puocci, A., Ceriello, A., Prattichizzo, F., Rizzo, M. R., et al. (2023) · Theranostics · doi:10.7150/thno.86831 · Cited by 73
“2020 [122] C57BL/6 mice Cardiac fibroblasts Liraglutide Inhibition of Ang II-AT1R-ROS Reactive oxygen”
Background
Metadata
- Authors
- Chen, P., Yang, F., Wang, W., Li, X., Liu, D., Zhang, Y., Yin, G., Lv, F., Guo, Z., Mehta, J. L., & Wang, X.
- Affiliations
- Zhengzhou University (CN)
- Henan Medical University (CN)
- First Affiliated Hospital of Xinxiang Medical University (CN)
- Central Arkansas Veterans Healthcare System (US)
- Corresponding author
- Mehta, Jawahar L.
- Wang, Xianwei
- ORCID
- Venue
- Journal of Cardiovascular Pharmacology and Therapeutics
- Publisher
- SAGE Publications
- Published
- 2020-07-20
- Volume
- 26
- Issue
- 2
- Pages
- 179-188
- ISSN
- 1074-2484 (ISSN-L)
- 1940-4034
- OpenAlex
- W3044882533
- Cited by
- 31
- References
- 47
- Citations by year
- 2026: 4 · 2025: 3 · 2024: 4 · 2023: 5 · 2022: 10 · 2021: 5
- FWCI
- 3.09
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
- Locations
- Journal of Cardiovascular Pharmacology and Therapeutics (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Natural Science Foundation of China (U1804166 and 81873459)
- henan university (19HASTIT004)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Fibrosis and Remodeling
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Renin-Angiotensin System Studies
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Keywords
- liraglutide, myocardial fibrosis, angiotensin II, angiotensin II type 1 receptor, reactive oxygen species, hypertension, GLP-1 receptor agonists, cardiac fibroblasts, collagen expression, losartan, cardioprotection
- MeSH terms
- Liraglutide, Animals, Fibrosis, Heart, Hypertension, Male, Mice, Inbred C57BL, Myocardium, Reactive Oxygen Species, Receptor, Angiotensin, Type 1, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Liraglutide Attenuates Myocardial Fibrosis via Inhibition of AT1R-Mediated ROS Production in Hypertensive Mice. https://app.cochat.ai/papers/10.1177/1074248420942007
- The paper
- Chen, P., Yang, F., Wang, W., Li, X., Liu, D., Zhang, Y., Yin, G., Lv, F., Guo, Z., Mehta, J. L., & Wang, X. (2021). Liraglutide Attenuates Myocardial Fibrosis via Inhibition of AT1R-Mediated ROS Production in Hypertensive Mice. Journal of Cardiovascular Pharmacology and Therapeutics. https://doi.org/10.1177/1074248420942007
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.